An interventional study of SUPERNOVA and NASAL MASK in Aortic Stenosis, sponsored by Ankara Bilkent Sehir Hastanesi. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-08-29.
Sponsored by Ankara Bilkent Sehir Hastanesi · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Aortic Valve Stenosis with a site in Turkey — 9 open to participants now, 9 under way, 2 of them phase 3. Aortic Valve Stenosis · Turkey.
Among the 14 studies in Aortic Valve Stenosis with a site in Turkey, this one is one of 4 that started in 2025, is one of 6 with no phase, and was the 11th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →9 of the 14 studies in Aortic Valve Stenosis with a site in Turkey are open now. Recruiting first, the newest first:
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 18+
Novartis Pharmaceuticals · Sites in Turkey, United States, Austria and 8 more countries
Ages 2–11
Medipol University · Sites in Turkey
Ages 18–85
Novartis Pharmaceuticals · Sites in Turkey, United States, Argentina and 20 more countries
Ages 6–11
Aristotle University Of Thessaloniki · Sites in Turkey, Canada, Germany and 3 more countries
Ages 18–85
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 4 started in 2025.
This study's planned enrollment of 100 is below the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 60 across the 8 interventional studies, 87 across the 6 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 14 have an industry lead sponsor. The 10 most frequent:
Ankara Bilkent Sehir Hastanesi is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Ankara Bilkent Sehir Hastanesi has 1 study filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Aortic Valve Stenosis with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07794436Istanbul University - CerrahpasaAssociation Between Changes in Aortic Valve Area and Pulmonary Congestion After Transcatheter Aortic Valve Implantation | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Aortic Valve Stenosis with a site in Turkey, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
With increasing life expectancy, the geriatric population continues to grow. According to the Turkish Statistical Institute (TÜİK), the average life expectancy in Turkey between 2021 and 2023 is 77.3 years. As the number of elderly surgical patients rises, optimizing anesthesia care is critical to reducing complications and improving clinical outcomes. In elderly patients with severe aortic stenosis, traditional surgical aortic valve replacement poses a high risk of complications. Consequently, Transcatheter Aortic Valve Implantation (TAVI) has emerged as a preferred, less invasive alternative. Due to technological advancements and shorter procedure durations, TAVI is increasingly performed under sedation rather than general anesthesia. However, sedation carries risks, including hypoxemia and hypoventilation, primarily due to sedative-induced respiratory depression.
Pulse oximetry, the traditional monitoring method, measures only peripheral oxygen saturation and does not provide early detection of apnea or hypoventilation. Therefore, monitoring end-tidal carbon dioxide (EtCO₂) during sedation has gained importance. The American Society of Anesthesiologists (ASA) recommends EtCO₂ monitoring during sedation. However, obtaining accurate EtCO₂ values via nasal cannulas is technically challenging. Open sampling ports and high oxygen flow rates can cause dilution or loss of exhaled CO₂, resulting in inaccurate readings.
The SuperNO₂VA™ nasal mask (Vyaire Medical, USA) addresses these limitations with an integrated CO₂ sampling port and the ability to provide positive airway pressure. This facilitates more accurate EtCO₂ monitoring and better ventilatory support compared to standard nasal cannulas. Prior studies have demonstrated that the SuperNO₂VA mask significantly reduces the risk and severity of hypoxia in high-risk patients during sedated endoscopic procedures. It prevents upper airway collapse and increases ventilated lung surface area, without causing clinically significant hypercapnia or CO₂ retention.
This study aims to compare the incidence of hypoxia in patients aged 65 years and older undergoing TAVI under sedation using either the SuperNO₂VA nasal mask or a conventional nasal oxygen mask. Secondary outcomes include the evaluation of intraoperative hypercapnia or hypocapnia and the assessment of postoperative respiratory complications.
The continuous increase in life expectancy has led to steady growth in the geriatric population. According to the Turkish Statistical Institute (TÜİK), the average life expectancy in Turkey from 2021 to 2023 is 77.3 years. In surgical geriatric patients, optimizing anesthesia care strategies is essential to reduce complications and enhance clinical outcomes. In patients with severe aortic stenosis, traditional surgical aortic valve replacement is associated with a high risk of complications. As a result, Transcatheter Aortic Valve Implantation (TAVI) has gained popularity. The anesthetic approach to TAVI varies based on surgical preference, procedural volume, echocardiography type, and team experience. Recent technological advancements and shorter procedural durations have made sedation-based anesthesia a preferred option. However, sedation may result in complications such as hypoxemia and hypoventilation due to central respiratory depression from sedative agents. Pulse oximetry, a conventional respiratory monitoring method, measures only peripheral oxygen saturation and may delay the detection of hypoventilation or apnea. In sedated patients receiving supplemental oxygen, measuring exhaled carbon dioxide (CO2) becomes essential. The American Society of Anesthesiologists (ASA) has endorsed the use of end-tidal capnography (EtCO2) as a standard for monitoring sedation. While capnography surpasses pulse oximetry in detecting hypoventilation and apnea, accurate EtCO2 measurement during deep sedation remains technically challenging due to dilution of exhaled gases from open nasal cannula sampling ports and high oxygen flow rates. The SuperNO2VA™ nasal mask (Vyaire Medical, USA) is an innovative device designed to overcome these challenges. It features an integrated CO2 sampling port and provides positive airway pressure, thereby allowing for accurate EtCO2 measurement and improved respiratory support compared to standard nasal oxygen masks. Prior research has shown that the SuperNO2VA mask significantly reduces both the frequency and severity of hypoxia in high-risk patients undergoing sedated endoscopic procedures. This device also helps prevent upper airway collapse and enhances lung ventilation. Importantly, its use has not been associated with clinically significant hypercapnia or CO2 retention. The objective of this study is to compare the incidence of hypoxia in patients over 65 years of age undergoing TAVI under sedation, using either the SuperNO2VA nasal mask or a standard nasal oxygen mask. In minimally invasive procedures such as TAVI in the geriatric population, accurate evaluation of hypoxia and hypercapnia is critical. Traditional oxygen delivery methods may be insufficient in preventing hypoxia and predicting CO2 disturbances. Based on previous studies, it is hypothesized that the SuperNO2VA mask will reduce hypoxia and improve detection of hypo/ hypercapnia via continuous EtCO2 monitoring. No specific risk is anticipated for participants in this study. A prospective, randomized controlled trial is planned, enrolling 100 patients via computer generated randomization in a 1:1 ratio (SuperNO2VA group: 50; control group: 50). In patients undergoing TAVI under sedation without endotracheal intubation, the SuperNO2VA group will receive oxygen via the nasal mask delivering positive airway pressure, while the control group will receive oxygen through a standard nasal mask. Oxygen flow will be adjusted to maintain SpO2
Preoperative parameters to be assessed:
Age and sex Height, weight, Body Mass Index (BMI) ASA Physical Status Classification Comorbidity evaluation Smoking history ARISCAT score parameters
Intraoperative parameters to be assessed:
Duration of anesthesia Occurrence of complications (e.g., need for intubation, resuscitation, bronchospasm) Incidence of hypoxia (SpO2 \< 90% for >10 seconds) Continuous EtCO2 monitoring Arterial blood gas measurements (PaO2, PaCO2) Peripheral oxygen saturation (SpO2) will be monitored continuously and recorded throughout the preoperative, intraoperative, and postoperative periods, totaling 12 hours. Data will be analyzed using SPSS version 27 (IBM Corporation, Armonk, NY, USA). Descriptive statistics will summarize baseline characteristics. The incidence of hypoxia between groups will be compared using Fisher's Exact Test. Multivariate logistic regression will be used to identify factors associated with hypoxia or hypercapnia. Statistical significance will be defined as p \< 0.05.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Device: SUPERNOVA
Device: NASAL MASK
In the intervention group, oxygen is delivered using the SuperNO2VA™ nasal positive airway pressure mask (Vyaire Medical, USA), which differs from conventional nasal oxygen delivery systems by providing continuous positive airway pressure (CPAP) through a sealed nasal interface. This mask also includes an integrated sampling port for accurate end tidal carbon dioxide (EtCO2) monitoring. The aim is to reduce the incidence of hypoxia and allow for better detection and prevention of hypo/hypercapnia during sedation in elderly patients undergoing TAVI without intubation. The use of positive pressure is intended to prevent upper airway collapse, maintain functional residual capacity, and improve gas exchange during sedation.
Traditional nasal cannulas only provide passive oxygen flow. End-tidal CO2 measurement is being conducted with Capnostream™ 35 Portable Respiratory Monitor.
Number of Participants Experiencing Hypoxia (SpO₂ < 90% for >10 Seconds)
Each patient included in the study will be monitored noninvasively with a pulse oximeter for oxygen saturation when taken to the operating room. The pulse oximeter will be placed on the index finger of the right hand. Oxygen saturation will be recorded as a numerical value between 0-100. Values below 90 will be evaluated as hypoxia and intervention will be made. Values below 90 will be evaluated as hypoxia and appropriate intervention will be made. A drop in SpO₂ below 90% lasting longer than 10 seconds will be recorded as hypoxia.
Time frame: 12 hours
Number of Participants with Hypotension (MAP < 65 mmHg
Each patient included in the study will be noninvasively monitored for arterial blood pressure upon arrival in the operating room. A standard noninvasive blood pressure cuff will be placed on the left upper arm. Arterial blood pressure values will be recorded in mmHg as systolic, diastolic, and mean arterial pressure (MAP). A MAP value below 65 mmHg will be considered hypotension, and appropriate intervention will be performed.
Time frame: 12 hours
Number of Participants with Hypoxemia (PaO2 < 60 mmHg)
Following the modified Allen test, arterial cannulation will be performed primarily from the radial artery under ultrasound guidance. Arterial blood gas analysis will be performed intraoperatively. The arterial partial pressure of oxygen (PaO2) will be measured and recorded in mmHg. A PaO2 value below 60 mmHg will be considered significant hypoxemia, and appropriate interventions will be undertaken.
Time frame: 12 hours
Number of Participants with Hypercapnia or Hypocapnia (PaCO2 > 45 or < 35 mmHg)
Following the modified Allen test, arterial cannulation will be performed primarily from the radial artery under ultrasound guidance.Arterial blood gas analysis will also include the measurement of arterial partial pressure of carbon dioxide (PaCO2). Values will be recorded in mmHg. A PaCO2 level above 45 mmHg will be interpreted as hypercapnia, while values below 35 mmHg will indicate hypocapnia. Clinical interventions will be made accordingly.
Time frame: 12 hours
Mean and Abnormal EtCO2 Levels During Sedation (EtCO2 < 30 or > 50 mmHg)
End-tidal carbon dioxide (EtCO2) monitoring will be performed continuously throughout the intraoperative period using a capnograph connected to the anesthesia circuit. EtCO2 values will be recorded in mmHg. Values outside the normal physiological range (35-45 mmHg) will be evaluated in the context of ventilation status. EtCO2 \< 30 mmHg will be considered as hypocapnia, while EtCO2 \> 50 mmHg will be interpreted as hypercapnia, and necessary interventions will be carried out.
Time frame: 12 hours
Number of Participants Experiencing Intraoperative Complications (Intubation, Resuscitation, or Bronchospasm)
Intraoperative complications will be evaluated and recorded. These include the need for endotracheal intubation, the need for resuscitation, and the occurrence of bronchospasm. Each event will be documented with its timing and clinical context. All interventions performed in response to these complications will also be recorded in detail. Patients who develop any of these complications intraoperatively will be excluded from the study.
Time frame: 12 hours
Plan to share: No
Started May 2025 (actual). Primary completion is estimated for Jan 2026, 8 months after the start.
Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 8 months is below that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ankara Bilkent Sehir Hastanesi